Purpose: Androgens may have a role in bladder carcinogenesis. We studied whether 5a-reductase inhibitors were associated with bladder cancer specific mortality in a population based cohort of men with bladder cancer. Materials and Methods: The study cohort consisted of 10,720 Finnish men with bladder cancer newly diagnosed in 1997 to 2012 who were identified in a national cancer registry. Median followup was 4.17 years after bladder cancer diagnosis. We analyzed the HR and 95% CI of the risk of bladder cancer death by 5a-reductase inhibitor administration using Cox regression adjusted for age, gender, comorbidities, primary bladder cancer treatment and tumor extent at diagnosis. Lag time analyses were performed to assess the long-term risk association. Simultaneous administration a-blockers was considered to estimate possible confounding by indication. Results: Administering 5a-reductase inhibitors before bladder cancer diagnosis was associated with a lower risk of bladder cancer death (HR 0.84, 95% CI 0.73e0.97). The risk decrease became stronger with years of use. Conversely prediagnostic administration of a-blockers was not associated with bladder cancer survival (HR 1.02, 95% CI 0.91e1.13). Similarly 5a-reductase inhibitor administration after diagnosis was associated with a decreased risk of bladder cancer death (HR 0.77, 95% CI 0.68e0.88). Bladder cancer survival was not associated with a-blockers (HR 0.98, 95% CI 0.90e1.07). The risk decrease due to 5a-reductase inhibitors persisted up to 5 years. Conclusions: Patients who receive 5a-reductase inhibitors have improved disease specific survival after bladder cancer diagnosis compared to those who do not receive them while a-blockers were not associated with survival. This supports the benefits of 5a-reductase inhibitors in bladder cancer.
UROTHELIAL bladder cancer is the sixth most common cancer type among men worldwide. 1 More than 70% to 80% of bladder cancers are superficial and treatable with TURB, often combined with intravesical instillation. In 25% of cases bladder cancer infiltrates the muscle layer of the bladder wall. In these cases radical cystectomy combined with chemotherapy is often needed. Fewer than 10% of bladder cancers have already metastasized by diagnosis and they are palliatively treated with chemotherapy and radiation. Tumors are also classified by cytology into low The corresponding author certifies that, when applicable, a statement(s) has been included in the manuscript documenting institutional review board, ethics committee or ethical review board study approval; principles of Helsinki Declaration were followed in lieu of formal ethics committee approval; institutional animal care and use committee approval; all human subjects provided written informed consent with guarantees of confidentiality; IRB approved protocol number; animal approved project number.
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or high grade with high grade the most malignant and potentially invasive type. 2 Superficial low grade bladder cancer often recurs but disease specific survival is excellent. This is not the case for muscle infiltrating invasive cancer, which has a 5-year survival rate of 50% to 65%. Metastatic disease is still incurable and life expectancy is less than 16 months. 3 The prevalence of bladder cancer is higher in men than in women. To our knowledge the reason for the gender difference is unknown but androgens were proposed to have an impact on urothelial carcinogenesis and androgen receptor signaling may promote the growth of urothelial cancer cells. 4 The importance of androgens in urothelial bladder cancer was supported by a recent study showing a reduced incidence of bladder cancer in men who received the 5-ARI finasteride or dutasteride compared to nonusers. 5 These drugs inhibit conversion of testosterone to dihydrotestosterone, a more potent activator of androgen signaling.
The enzyme 5a-reductase is expressed mainly in the prostate and 5-ARIs are mainly used to manage benign prostatic hyperplasia. However, 5a-reductase is also expressed by urothelial cancer cells and dihydrotestosterone affects the growth of those cells. 6, 7 Therefore, it can be presumed that 5-ARIs would benefit patients with bladder cancer. However, currently to our knowledge no published studies have described how 5-ARIs may affect the bladder cancer prognosis.
We performed a population based cohort study in Finland to estimate whether 5-ARI use is associated with bladder cancer prognosis. Our hypothesis was that the prognosis would be better among men who received 5-ARI. As 5-ARIs are used to treat benign prostate hyperplasia and lower urinary tract symptoms caused by benign prostate hyperplasia, 5-ARI users are more likely than nonusers to be under urologist supervision, creating possible selection bias. To assess and control for this bias we additionally analyzed the risk association with a-blockers, which are used partly for the same indications.
MATERIALS AND METHODS

Study Population
We collected the records of all urothelial cancers of the bladder diagnosed in Finland during 1997 to 2012 from the comprehensive national FCR (Finnish Cancer Registry) based on ICD-10 codes (C67.0-C67.9). 8 A total of 10,720 men were included in study. Available data included date of cancer diagnosis, tumor extent (localized, locally advanced or metastatic), primary treatment (surgery vs other), and the date and the cause of death. The FCR data were linked to the HILMO information based on personal unique identification numbers. HILMO data contained diagnoses and procedures recorded at hospital contacts at Finnish health care units in 1997 to 2012. 9 The HILMO data were used to evaluate comorbidities (diabetes, hypercholesterolemia and hypertension) and obtain information on the timing and the number of endoscopic and open surgical procedures for bladder cancer after diagnosis. Surgical procedures were identified by procedure codes KCD02, KCD05, KCD32, KCC00, KCC10 and KCC20 (supplementary Appendix, http:// jurology.com/).
Medication Information
The study cohort was linked to the national prescription database managed by the SII to obtain data on 5-ARI (finasteride and dutasteride) medication purchases in 1997 to 2012. Additionally, data on cholesterol lowering, antihypertensive and antidiabetic drug purchases were also collected. The database provided detailed information on each medication purchase, including the date of purchase, ATC (Anatomical Therapeutic Chemical) code, package size and dose.
As part of the national health insurance available to all Finnish citizens, SII partly covers costs of physician prescribed drug purchases. 10 The reimbursement is available to all Finnish citizens. Each reimbursed prescription purchase is recorded regardless of the rate of SII cost coverage. Because in Finland a-blockers and 5-ARIs are available only by prescription, they are comprehensively recorded by the database. The only exception is 1 mg finasteride used to treat androgenetic alopecia. Overthe-counter medications and medications used during inpatient procedures are also not recorded by the database.
Statistical Analysis
Age distribution, tumor and treatment characteristics, and the prevalence of comorbidities were compared by 5-ARI use before and after the bladder cancer diagnosis. We applied the chi-square test to test for statistical significance of differences in categorical variables and the Mann-Whitney U test for noncategorical variables. Analyses of prediagnostic and post-diagnostic use were done in separate models.
Logistic regression was used to calculate the OR and 95% CI of the risk of 2 or more, or 5 or more TURBs after bladder cancer diagnosis. The logistic regression model was adjusted for age and comorbidities.
We analyzed the HR and 95% CI of the risk of bladder cancer death using Cox regression adjusted for age, gender, comorbidities, primary bladder cancer treatment (surgery vs other) and tumor extent at diagnosis (localized vs metastatic). Unknown tumor extent was included in analysis as 1 category. The time metric was years and months since bladder cancer diagnosis. Followup continued until death, emigration or the common closing date of December 31, 2012, whichever was first.
Medication use was divided into prediagnostic and post-diagnostic administration according to the year of drug purchase. Use at the year of diagnosis was included in post-diagnostic use. Patients who received 5-ARIs were stratified into 2 subgroups by the median number of 5-ARI doses per year. Similar stratifications were done for a-blockers.
Prediagnostic 5-ARI receipt was analyzed as a time fixed variable considering all use between 1997 and the year of diagnosis. Post-diagnostic 5-ARI receipt was analyzed as a time dependent variable with user status and annual dose updated separately for each followup year based on the annual recorded purchases. We entered a-blocker and 5-ARI receipt in the regression model together to consider simultaneous use.
Long-term risk associations were evaluated in lag time analyses with medication use lagged forward in followup. In the 3-year lag time analysis we estimated the effects of 5-ARI receipt from 3 years earlier, eg for end points in 2005 we used 5-ARI exposure in 2002.
All statistical p-values are 2-sided. All analyses were performed with IBMÒ SPSSÒ Statistics.
RESULTS
Population Characteristics
In the study population of 10,720 men median followup was 4.17 years after bladder cancer diagnosis. A total of 6,100 participants (56.9%) died during followup. The number of deaths caused by bladder cancer was 2,332 (21.8%).
Drug Users
Before Diagnosis. Patients who received 5-ARI and a-blocker were generally slightly older than those who did not receive the medications. Median age among 5-ARI recipients was 78 years, which was 2 years greater than the age of a-blocker users. There was no statistically significant difference in the proportion of all cause or bladder cancer death between 5-ARI and a-blocker users. However, compared to nonusers 5-ARI and a-blocker recipients had significantly lower all cause and bladder cancer specific mortality. At diagnosis 5-ARI users more often had metastatic bladder cancer than a-blocker users (14.5% vs 13.0%) but there were more localized bladder cancers among men who received a-blocker than 5-ARI (60.8 vs 59.0) (supplementary table 1, http://jurology.com/).
There was no statistically significant difference between 5-ARI and a-blocker users in the median Charlson comorbidity index or the median number of surgical procedures after bladder cancer diagnosis. Those receiving a-blocker were treated more often with cystoprostatectomy than those receiving 5-ARI (12.6% vs 10.6%). However, there was no significant difference between men who received 5-ARI and a-blocker in the proportion treated with radiation and chemotherapy (supplementary table 1, http://jurology.com/).
After Diagnosis. For post-diagnostic use patients receiving 5-ARI and a-blocker were almost the same age with the former being a year older (75 years) than a-blocker users. All cause mortality was lower in 5-ARI and a-blocker cases (45.5% and 51.2%), as was bladder cancer specific morality (14.1% and 17.9%, respectively). However, compared to nonusers those on 5-ARI and a-blocker had lower all cause and bladder cancer specific mortality. Men receiving 5-ARI tended to have more localized tumors at diagnosis than those receiving a-blocker (66.9% vs 65.5%) while a metastatic tumor extent was more common among those on a-blocker (9.5% vs 8.6%) (supplementary table 1, http://jurology.com/).
Fewer surgical procedures had been done in men on 5-ARI than on a-blocker (1 vs 2). Additionally, 5-ARI users underwent fewer cystectomies (6.8% vs 9.4%), less radiation (8.4% vs 11.5%) and less chemotherapy (20.1% vs 22.8%) than those on a-blocker. There was no statistically significant difference between 5-ARI and a-blocker cases in the Charlson comorbidity index (supplementary table 1 figure) . The decreased risk did not clearly depend on the annual dose but rather became stronger with years of use. On stratified analysis the risk decrease was significant only after 3 years of administration.
Conversely prediagnostic use of a-blockers was not associated with bladder cancer survival (HR 1.02, 95% CI 0.92e1.14, supplementary table 2, http://jurology.com/, and part b of figure) . Again, the risk association did not depend on the annual dose or the duration of use.
After Diagnosis. The administration of 5-ARIs after bladder cancer diagnosis was associated with a decreased risk of cancer specific death on multivariable adjusted analysis (HR 0.77, 95% CI 0.68e0.88, supplementary table 2, http://jurology. com/). Also, for post-diagnostic use the risk decrease was dose dependent and inversely correlated with the yearly 5-ARI dose.
Again, a-blocker administration was not related to bladder cancer survival (HR 0.98, 95% CI 0.90e1.07, supplementary table 2, http://jurology. com/). However, at a high dose (total more than 210 mg) a-blockers were also associated with lower bladder cancer mortality than that in nonusers. Nevertheless, men receiving 5-ARI showed a greater risk reduction than men on a-blocker, especially after multivariable adjustment.
Lag Time Analysis
The decreased risk of bladder cancer death became statistically nonsignificant within 3 years, although the risk estimate was lower even at 5 years (table 1) .
a-Blocker and 5a-Reductase Inhibitor Association with Number of Transurethral Bladder Resections
Among endoscopically treated patients 5-ARI and a-blocker administration was associated with a lower risk of multiple TURB procedures after the bladder cancer diagnosis compared to nonusers (table 2). The association was statistically significant only among those who received a-blocker but similar risk estimates were also observed in those on 5-ARI.
DISCUSSION
Men on 5-ARIs were at lower risk for bladder cancer death than nonusers. This risk difference was not observed among men on a-blocker even after adjustment for comorbidities and other background variables. Indications for the use of these drugs overlapped but only 5-ARIs affected androgen metabolism. Thus, our results support the role of androgens in bladder cancer progression.
To our knowledge we report the first study to clarify the association between androgen metabolism targeted by 5ARIs and bladder cancer survival. In a prior study 5-ARIs were associated with a lower risk of bladder cancer. 5 These findings were subsequently supported by a case-control study showing a decreased risk of bladder cancer in Taiwanese men on finasteride and a cohort study demonstrating decreased bladder cancer risk among a cohort of 228 Japanese men on 5-ARIs or androgen deprivation therapy for prostate cancer. 7, 11 The results of our study are in line with previous studies regarding the potential beneficial effects of 5-ARI in men with bladder Bladder cancer specific survival by 5a-reductase inhibitor (a) and a-blocker (b) use before bladder cancer diagnosis cancer. However, to our knowledge this is the first study to suggest the beneficial effects of 5-ARI and the role of androgens in bladder cancer progression. Interestingly androgen deprivation therapy for prostate cancer has also been linked to a decreased risk of BCa recurrence, further supporting the role of androgens in BCa. 12 The risk association with bladder cancer death among men on 5-ARI depended on the annual dose and the cumulative duration of use. This suggests a causal association. However, noncausal explanations must be considered as well.
The indication for 5-ARI administration in our study was symptomatic benign prostatic hyperplasia. Our data did not cover 5-ARI use for male pattern baldness. Men with lower urinary tract symptoms undergo urological examination more often than men without such symptoms. Therefore, bladder tumors could be detected earlier and at a more curable phase in such men, generating lead time bias. This bias was evaluated by also analyzing a-blockers, a drug group with similar indications for use in men who were thus affected by the same bias but with a completely different mechanism of action. The risk decrease was observed only in men receiving 5-ARI, strongly suggesting that lead time bias did not explain the observed risk difference. Further, lead time bias would presumably mean fewer TURBs required in 5-ARI and a-blocker users than to nonusers. A significantly lower risk of multiple TURBs was observed only in men on a-blocker compared to nonusers, again arguing against lead time bias in those on 5-ARI.
Another possible noncausal explanation could be more efficient treatment of bladder cancer in men on 5-ARIs. Such men could be presumed to be more generally fit and more often suitable candidates for cystectomy. However, patients receiving 5-ARI were less often treated with cystectomy, which further argues against healthy user bias.
The strength of our study is the ability to compare bladder cancer survival between 5-ARI users and a-blocker users. While a-blockers and 5-ARIs have completely different mechanisms of action, they are often used for similar indications. Therefore, these comparisons allowed us to evaluate the impact of selection bias between users and nonusers. Interestingly the survival benefit was observed only among men using 5-ARIs, supporting a causal association.
The data for the study were collected from nationwide databases which provided accurate information on drug purchases and bladder cancer deaths. The exact drug use history enabled us to separately evaluate medication use before and after bladder cancer diagnosis, and evaluate the dose and time related dependence on the risk of bladder cancer death as well as simultaneous use of 5-ARIs and a-blockers.
Finasteride treatment of androgenetic alopecia was not recorded by the SII, causing bias toward the null. However, this did not interfere with our conclusion of improved BCa survival among men on 5-ARI. As our study is a retrospective comparison and 5-ARI use was not randomized, confounding due to background factors such as socioeconomic inequality could have affected the observed survival differences. Information on intravesical therapy was also not available in the national database. On the other hand, there was a lack of data on the ablocker group as well so that this did not affect comparisons between 5-ARI and a-blocker users.
We had no information on participant lifestyle related risk factors such as tobacco smoking, nutrition or physical activity, which may have had an impact on the prognosis of cancer. These factors may have differed between drug users and nonusers. However, the bias caused by lifestyle choices was not related to the amount of drug received. Therefore, the dose dependent risk trends seen for 5-ARI administration were likely related to the direct effect of 5-ARIs on bladder cancer progression.
CONCLUSIONS
To our knowledge this is the first study to estimate the role of 5-ARI administration in the prognosis of bladder cancer. Men on 5-ARI had better disease specific survival after a bladder cancer diagnosis 
